In Silico Modeling Details Common Binding Mode of GHRP-6 and Novel Analogs at the Ghrelin Receptor
Background
Ghrelin is a critical peptide hormone with diverse functions, including stimulating growth hormone release, regulating food intake, and providing cytoprotective effects. Its receptor, the growth hormone secretagogue receptor GHS-R1a, is a key target for developing therapies. Designing novel agonists for this receptor could lead to treatments for conditions involving metabolic dysregulation or growth deficiencies. However, understanding precisely how different peptide agonists bind to GHS-R1a is a significant challenge. This study focuses on a new family of internally cyclized peptides designed as ghrelin analogs, aiming to create a detailed structural model of their interaction with the receptor to guide the rational design of more effective compounds.
Study Design
This study employed an in silico (computational) strategy to model the binding of novel ghrelin analog peptides, A228 and A233, to the GHS-R1a receptor. They first built a high-quality 3D model of GHS-R1a using several known G protein-coupled receptor structures as templates. The best model was selected via preliminary molecular docking with known agonists, ghrelin and GHRP-6. The binding modes of A228 and A233 were then assessed and compared. Finally, the peptide-receptor complexes were inserted into a simulated cell membrane (POPC) and subjected to a 100 ns molecular dynamics simulation using the CHARMM36 force field to test the stability of the interactions over time.
Results
The molecular docking and dynamic simulations revealed a common binding mode shared by ghrelin, GHRP-6, A228, and A233, despite their structural differences. A key interaction involves the N-terminal of the peptides, which consistently orients itself to interact with the amino acid residue E124 on the GHS-R1a receptor. Additionally, the first aromatic residue on each peptide was observed to engage with an aromatic cluster on the receptor, specifically involving residues F279, F309, and F312. This conserved binding pattern allowed the researchers to propose a preliminary pharmacophore model for GHS-R1a agonists.
The proposed pharmacophore model consists of two critical features: a positively charged amine group and an aromatic ring, separated by an approximate distance of 0.79 nm. This specific spatial arrangement appears essential for effective receptor binding and activation. This finding provides a structural blueprint for designing new, potentially more potent ghrelin analogs by ensuring new molecules possess these key features at the correct distance.
Key Findings
- A common binding mode was identified for ghrelin, GHRP-6, A228, and A233 at the GHS-R1a receptor.
- The peptide N-terminus consistently interacts with the receptor's E124 residue.
- An aromatic residue on the peptides interacts with an aromatic cluster on the receptor (F279, F309, F312).
- A preliminary pharmacophore model for GHS-R1a agonists was proposed: a positive amine and an aromatic ring.
- The key features in the pharmacophore model are separated by a distance of approximately 0.79 nm.
Why It Matters
This computational work provides a detailed structural roadmap for creating new growth hormone secretagogues. For researchers and peptide developers, the identified pharmacophore—a positive charge and an aromatic ring separated by 0.79 nm—is a concrete design principle. This model can accelerate the discovery of novel ghrelin mimetics by allowing scientists to computationally screen and design compounds with a higher probability of successfully binding to and activating the GHS-R1a receptor. While this is a foundational, pre-clinical modeling study, it significantly refines the search parameters for new drugs, potentially reducing the time and cost of development. This moves the field closer to creating more stable, potent, or specific ghrelin analogs for therapeutic use in metabolic and growth-related disorders.
ghrp-6
ghrelin
ghs-r1a
in silico
molecular docking
molecular dynamics
